Conall O'CLeirigh

Conall O'CLeirigh

Auto-generated profile, based on publicly available information

Conall O'CLeirigh

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2014 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
COConall O’cLeirigh
Conall O’cLeirigh
SVSarah E. Valentine
Sarah E. Valentine
MPMegan Pinkston
Megan Pinkston
DHDebra Herman
Debra Herman
CBC. Andres Bedoya
C. Andres Bedoya
SSSteven A. Safren
Steven A. Safren

10 July 2015 in Archives of Sexual Behavior
Verified
Journal Article
Closed access
PDF file
MBMichael S. Boroughs
Michael S. Boroughs
SVSarah E. Valentine
Sarah E. Valentine
GIGail H. Ironson
Gail H. Ironson
JSJillian C. Shipherd
Jillian C. Shipherd
SSSteven A. Safren
Steven A. Safren
COConall O’cLeirigh
Conall O’cLeirigh

1 September 2019 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
COConall O’cLeirigh
Conall O’cLeirigh
SSSteven A. Safren
Steven A. Safren
STS. Wade Taylor
S. Wade Taylor
BGBrett M. Goshe
Brett M. Goshe
CBC. Andres Bedoya
C. Andres Bedoya
JSJillian C. Shipherd
Jillian C. Shipherd

13 January 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
PCPeter R Chai
Peter R Chai
SCStephanie Carreiro
Stephanie Carreiro
BIBrendan J Innes
Brendan J Innes
RRRochelle K Rosen
Rochelle K Rosen
COConall O'CLeirigh
Conall O'CLeirigh
EBEdward W Boyer
Edward W Boyer
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

19 March 2019 in AIDS Care
Verified
Journal Article
Closed access
MMMatthew Mimiaga
Matthew Mimiaga
DPDavid W. Pantalone
David W. Pantalone
KBKatie B. Biello
Katie B. Biello
JHJackie M. White Hughto
Jackie M. White Hughto
JFJohn Frank
John Frank
SSSteven A. Safren
Steven A. Safren
Men who have sex with men (MSM) continue to be the largest risk group for HIV infections in the U.S., where crystal methamphetamine abuse heightens risk for HIV infection through greater engagement in condomless anal sex (CAS). Existing treatments lack attention to replacement activities or the role of depressed mood. Behavioral activation (BA) is an evidence-based approach for depression that involves identifying and participating in pleasurable, goal-directed activities. We hypothesize, for MSM abusing crystal methamphetamine, re-learning how to engage in non-drug-using aspects of life would facilitate their ability to benefit from sexual risk reduction (SRR) counseling. Project IMPACT was a pilot randomized-controlled-trial. Forty-six MSM at sexual risk of acquiring HIV who met DSM-IV criteria for crystal methamphetamine dependence were enrolled. Of those MSM, 41 were randomized: 21 were assigned to the intervention, two sessions of SRR, ten sessions of BA with SRR, and one session of relapse prevention; 20 participants were assigned to a control condition (two sessions of SRR). At the acute post-intervention visit, intervention participants reported an average of 3.2 CAS acts with men who were HIV-infected or whose status they did not know, compared to 4.5 among control participants (β = −0.36; 95% CI: −0.69, −0.02; p = 0.035). At the 6-month post-intervention visit, intervention participants reported 1.1 CAS acts with men who were HIV-infected or whose status they did not know compared to 2.8 among control participants (β = −0.95; 95% CI: −1.44, −0.46; p < 0.0001). Similarly, intervention participants reported 1.0 CAS acts under the influence of crystal methamphetamine with men who were HIV-infected or whose status they did not know compared to 2.5 among control participants (β = −0.87; 95% CI: −1.38, −0.36; p = 0.0005). Lastly, intervention participants reported more continuous days abstaining from crystal methamphetamine compared to control (50.1 vs. 39.0, respectively) (β = 0.25; 95% CI: 0.16, 0.34; p < 0.0001). Findings are encouraging, provide evidence of feasibility and acceptability, and demonstrate initial efficacy for reducing sexual risk for HIV and crystal methamphetamine use.

1 October 2018 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
COConall O'Cleirigh
Conall O'Cleirigh
MZMichael J. Zvolensky
Michael J. Zvolensky
JSJasper A. J. Smits
Jasper A. J. Smits
ALAllison K. Labbe
Allison K. Labbe
JCJessica N. Ba Coleman
Jessica N. Ba Coleman
DRDavid Rosenfield
David Rosenfield
Objective: Among people living with HIV, cigarette smoking rates are higher than among the general population, and anxiety, depression, and their disorders are common and associated with smoking and poorer outcomes during cessation. This study evaluated the efficacy of an integrated smoking cessation intervention, developed to target anxiety, depression, and smoking cessation concurrently among people living with HIV. Method: Smokers living with HIV who reported at least moderate motivation to quit smoking were randomized into a novel 9-week integrated intervention (QUIT), consisting of 1 psychoeducation (prerandomization) session and 9 weekly 1-hour sessions of cognitive behavioral therapy for smoking cessation and anxiety/depression plus nicotine replacement therapy, or a 9-week enhanced standard smoking intervention (ETAU), consisting of 1 psychoeducation session (prerandomization) and 4 brief weekly check-in sessions plus nicotine replacement therapy. All were instructed to make a quit attempt at week 6. Results: Seventy-two participants were enrolled, and 53 were randomized. 41/53 participants completed the active treatment phase of the study. 7-day point-prevalence abstinence, verified with expired carbon monoxide, was significantly higher among those in the integrated intervention than those in the enhanced standard intervention both end-of-treatment {[MQUIT = 59%, METAU = 9%; b = 5.60, 95% confidence interval: (2.64 to 8.56), t(332) = 3.72, P < 0.001]} and 6-months post-quit date {[MQUIT = 46%, METAU = 5%; b = 7.69, 95% confidence interval: (4.60 to 10.78), t(332) = 4.90, P < 0.001]}. Consideration of patterns of missingness did not alter the significance of these findings. Conclusions: The integrated intervention was associated with substantially higher short-term and long-term abstinence rates than the enhanced standard intervention. These data provide promising initial evidence supporting the benefits of an integrated anxiety–depression/smoking cessation program specifically tailored for people living with HIV.